Global Antisense and RNAi Therapeutics Market Research Report 2024, Forecast to 2032
Report Overview
Antisense and RNA interference (RNAi) therapeutics are types of molecular therapies that target specific genes or gene products to treat various diseases. They work at the molecular level and aim to modulate gene expression to achieve therapeutic effects.
The global Antisense and RNAi Therapeutics market size was estimated at USD 1284.20 million in 2023 and is projected to reach USD 2079.24 million by 2032, exhibiting a CAGR of 5.50% during the forecast period.
North America Antisense and RNAi Therapeutics market size was estimated at USD 366.92 million in 2023, at a CAGR of 4.71% during the forecast period of 2024 through 2032.
This report provides a deep insight into the global Antisense and RNAi Therapeutics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Antisense and RNAi Therapeutics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Antisense and RNAi Therapeutics market in any manner.
Global Antisense and RNAi Therapeutics Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Tekmira Pharmaceuticals
Arbutus Biopharma
Alnylam Pharmaceuticals
Antisense Therapeutics
Silence Therapeutics
Isis Pharmaceuticals
Sirnaomics
Santaris
Roche
Market Segmentation (by Type)
RNA Interference
Antisense RNA
Market Segmentation (by Application)
Hospital
Clinic
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Antisense and RNAi Therapeutics Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Antisense and RNAi Therapeutics, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.
Chapter 13 is the main points and conclusions of the report.
Antisense and RNA interference (RNAi) therapeutics are types of molecular therapies that target specific genes or gene products to treat various diseases. They work at the molecular level and aim to modulate gene expression to achieve therapeutic effects.
The global Antisense and RNAi Therapeutics market size was estimated at USD 1284.20 million in 2023 and is projected to reach USD 2079.24 million by 2032, exhibiting a CAGR of 5.50% during the forecast period.
North America Antisense and RNAi Therapeutics market size was estimated at USD 366.92 million in 2023, at a CAGR of 4.71% during the forecast period of 2024 through 2032.
This report provides a deep insight into the global Antisense and RNAi Therapeutics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Antisense and RNAi Therapeutics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Antisense and RNAi Therapeutics market in any manner.
Global Antisense and RNAi Therapeutics Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Tekmira Pharmaceuticals
Arbutus Biopharma
Alnylam Pharmaceuticals
Antisense Therapeutics
Silence Therapeutics
Isis Pharmaceuticals
Sirnaomics
Santaris
Roche
Market Segmentation (by Type)
RNA Interference
Antisense RNA
Market Segmentation (by Application)
Hospital
Clinic
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Antisense and RNAi Therapeutics Market
- Overview of the regional outlook of the Antisense and RNAi Therapeutics Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Antisense and RNAi Therapeutics Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Antisense and RNAi Therapeutics, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.
Chapter 13 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Antisense and RNAi Therapeutics
1.2 Key Market Segments
1.2.1 Antisense and RNAi Therapeutics Segment by Type
1.2.2 Antisense and RNAi Therapeutics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ANTISENSE AND RNAI THERAPEUTICS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Antisense and RNAi Therapeutics Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Antisense and RNAi Therapeutics Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ANTISENSE AND RNAI THERAPEUTICS MARKET COMPETITIVE LANDSCAPE
3.1 Global Antisense and RNAi Therapeutics Sales by Manufacturers (2019-2024)
3.2 Global Antisense and RNAi Therapeutics Revenue Market Share by Manufacturers (2019-2024)
3.3 Antisense and RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Antisense and RNAi Therapeutics Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Antisense and RNAi Therapeutics Sales Sites, Area Served, Product Type
3.6 Antisense and RNAi Therapeutics Market Competitive Situation and Trends
3.6.1 Antisense and RNAi Therapeutics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Antisense and RNAi Therapeutics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 ANTISENSE AND RNAI THERAPEUTICS INDUSTRY CHAIN ANALYSIS
4.1 Antisense and RNAi Therapeutics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ANTISENSE AND RNAI THERAPEUTICS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 ANTISENSE AND RNAI THERAPEUTICS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Antisense and RNAi Therapeutics Sales Market Share by Type (2019-2024)
6.3 Global Antisense and RNAi Therapeutics Market Size Market Share by Type (2019-2024)
6.4 Global Antisense and RNAi Therapeutics Price by Type (2019-2024)
7 ANTISENSE AND RNAI THERAPEUTICS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Antisense and RNAi Therapeutics Market Sales by Application (2019-2024)
7.3 Global Antisense and RNAi Therapeutics Market Size (M USD) by Application (2019-2024)
7.4 Global Antisense and RNAi Therapeutics Sales Growth Rate by Application (2019-2024)
8 ANTISENSE AND RNAI THERAPEUTICS MARKET CONSUMPTION BY REGION
8.1 Global Antisense and RNAi Therapeutics Sales by Region
8.1.1 Global Antisense and RNAi Therapeutics Sales by Region
8.1.2 Global Antisense and RNAi Therapeutics Sales Market Share by Region
8.2 North America
8.2.1 North America Antisense and RNAi Therapeutics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Antisense and RNAi Therapeutics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Antisense and RNAi Therapeutics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Antisense and RNAi Therapeutics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Antisense and RNAi Therapeutics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 ANTISENSE AND RNAI THERAPEUTICS MARKET PRODUCTION BY REGION
9.1 Global Production of Antisense and RNAi Therapeutics by Region (2019-2024)
9.2 Global Antisense and RNAi Therapeutics Revenue Market Share by Region (2019-2024)
9.3 Global Antisense and RNAi Therapeutics Production, Revenue, Price and Gross Margin (2019-2024)
9.4 North America Antisense and RNAi Therapeutics Production
9.4.1 North America Antisense and RNAi Therapeutics Production Growth Rate (2019-2024)
9.4.2 North America Antisense and RNAi Therapeutics Production, Revenue, Price and Gross Margin (2019-2024)
9.5 Europe Antisense and RNAi Therapeutics Production
9.5.1 Europe Antisense and RNAi Therapeutics Production Growth Rate (2019-2024)
9.5.2 Europe Antisense and RNAi Therapeutics Production, Revenue, Price and Gross Margin (2019-2024)
9.6 Japan Antisense and RNAi Therapeutics Production (2019-2024)
9.6.1 Japan Antisense and RNAi Therapeutics Production Growth Rate (2019-2024)
9.6.2 Japan Antisense and RNAi Therapeutics Production, Revenue, Price and Gross Margin (2019-2024)
9.7 China Antisense and RNAi Therapeutics Production (2019-2024)
9.7.1 China Antisense and RNAi Therapeutics Production Growth Rate (2019-2024)
9.7.2 China Antisense and RNAi Therapeutics Production, Revenue, Price and Gross Margin (2019-2024)
10 KEY COMPANIES PROFILE
10.1 Tekmira Pharmaceuticals
10.1.1 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
10.1.2 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
10.1.3 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product Market Performance
10.1.4 Tekmira Pharmaceuticals Business Overview
10.1.5 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
10.1.6 Tekmira Pharmaceuticals Recent Developments
10.2 Arbutus Biopharma
10.2.1 Arbutus Biopharma Antisense and RNAi Therapeutics Basic Information
10.2.2 Arbutus Biopharma Antisense and RNAi Therapeutics Product Overview
10.2.3 Arbutus Biopharma Antisense and RNAi Therapeutics Product Market Performance
10.2.4 Arbutus Biopharma Business Overview
10.2.5 Arbutus Biopharma Antisense and RNAi Therapeutics SWOT Analysis
10.2.6 Arbutus Biopharma Recent Developments
10.3 Alnylam Pharmaceuticals
10.3.1 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
10.3.2 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
10.3.3 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product Market Performance
10.3.4 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
10.3.5 Alnylam Pharmaceuticals Business Overview
10.3.6 Alnylam Pharmaceuticals Recent Developments
10.4 Antisense Therapeutics
10.4.1 Antisense Therapeutics Antisense and RNAi Therapeutics Basic Information
10.4.2 Antisense Therapeutics Antisense and RNAi Therapeutics Product Overview
10.4.3 Antisense Therapeutics Antisense and RNAi Therapeutics Product Market Performance
10.4.4 Antisense Therapeutics Business Overview
10.4.5 Antisense Therapeutics Recent Developments
10.5 Silence Therapeutics
10.5.1 Silence Therapeutics Antisense and RNAi Therapeutics Basic Information
10.5.2 Silence Therapeutics Antisense and RNAi Therapeutics Product Overview
10.5.3 Silence Therapeutics Antisense and RNAi Therapeutics Product Market Performance
10.5.4 Silence Therapeutics Business Overview
10.5.5 Silence Therapeutics Recent Developments
10.6 Isis Pharmaceuticals
10.6.1 Isis Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
10.6.2 Isis Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
10.6.3 Isis Pharmaceuticals Antisense and RNAi Therapeutics Product Market Performance
10.6.4 Isis Pharmaceuticals Business Overview
10.6.5 Isis Pharmaceuticals Recent Developments
10.7 Sirnaomics
10.7.1 Sirnaomics Antisense and RNAi Therapeutics Basic Information
10.7.2 Sirnaomics Antisense and RNAi Therapeutics Product Overview
10.7.3 Sirnaomics Antisense and RNAi Therapeutics Product Market Performance
10.7.4 Sirnaomics Business Overview
10.7.5 Sirnaomics Recent Developments
10.8 Santaris
10.8.1 Santaris Antisense and RNAi Therapeutics Basic Information
10.8.2 Santaris Antisense and RNAi Therapeutics Product Overview
10.8.3 Santaris Antisense and RNAi Therapeutics Product Market Performance
10.8.4 Santaris Business Overview
10.8.5 Santaris Recent Developments
10.9 Roche
10.9.1 Roche Antisense and RNAi Therapeutics Basic Information
10.9.2 Roche Antisense and RNAi Therapeutics Product Overview
10.9.3 Roche Antisense and RNAi Therapeutics Product Market Performance
10.9.4 Roche Business Overview
10.9.5 Roche Recent Developments
11 ANTISENSE AND RNAI THERAPEUTICS MARKET FORECAST BY REGION
11.1 Global Antisense and RNAi Therapeutics Market Size Forecast
11.2 Global Antisense and RNAi Therapeutics Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Antisense and RNAi Therapeutics Market Size Forecast by Country
11.2.3 Asia Pacific Antisense and RNAi Therapeutics Market Size Forecast by Region
11.2.4 South America Antisense and RNAi Therapeutics Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Antisense and RNAi Therapeutics by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)
12.1 Global Antisense and RNAi Therapeutics Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Antisense and RNAi Therapeutics by Type (2025-2032)
12.1.2 Global Antisense and RNAi Therapeutics Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Antisense and RNAi Therapeutics by Type (2025-2032)
12.2 Global Antisense and RNAi Therapeutics Market Forecast by Application (2025-2032)
12.2.1 Global Antisense and RNAi Therapeutics Sales (K MT) Forecast by Application
12.2.2 Global Antisense and RNAi Therapeutics Market Size (M USD) Forecast by Application (2025-2032)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Antisense and RNAi Therapeutics
1.2 Key Market Segments
1.2.1 Antisense and RNAi Therapeutics Segment by Type
1.2.2 Antisense and RNAi Therapeutics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ANTISENSE AND RNAI THERAPEUTICS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Antisense and RNAi Therapeutics Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Antisense and RNAi Therapeutics Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ANTISENSE AND RNAI THERAPEUTICS MARKET COMPETITIVE LANDSCAPE
3.1 Global Antisense and RNAi Therapeutics Sales by Manufacturers (2019-2024)
3.2 Global Antisense and RNAi Therapeutics Revenue Market Share by Manufacturers (2019-2024)
3.3 Antisense and RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Antisense and RNAi Therapeutics Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Antisense and RNAi Therapeutics Sales Sites, Area Served, Product Type
3.6 Antisense and RNAi Therapeutics Market Competitive Situation and Trends
3.6.1 Antisense and RNAi Therapeutics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Antisense and RNAi Therapeutics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 ANTISENSE AND RNAI THERAPEUTICS INDUSTRY CHAIN ANALYSIS
4.1 Antisense and RNAi Therapeutics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ANTISENSE AND RNAI THERAPEUTICS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 ANTISENSE AND RNAI THERAPEUTICS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Antisense and RNAi Therapeutics Sales Market Share by Type (2019-2024)
6.3 Global Antisense and RNAi Therapeutics Market Size Market Share by Type (2019-2024)
6.4 Global Antisense and RNAi Therapeutics Price by Type (2019-2024)
7 ANTISENSE AND RNAI THERAPEUTICS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Antisense and RNAi Therapeutics Market Sales by Application (2019-2024)
7.3 Global Antisense and RNAi Therapeutics Market Size (M USD) by Application (2019-2024)
7.4 Global Antisense and RNAi Therapeutics Sales Growth Rate by Application (2019-2024)
8 ANTISENSE AND RNAI THERAPEUTICS MARKET CONSUMPTION BY REGION
8.1 Global Antisense and RNAi Therapeutics Sales by Region
8.1.1 Global Antisense and RNAi Therapeutics Sales by Region
8.1.2 Global Antisense and RNAi Therapeutics Sales Market Share by Region
8.2 North America
8.2.1 North America Antisense and RNAi Therapeutics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Antisense and RNAi Therapeutics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Antisense and RNAi Therapeutics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Antisense and RNAi Therapeutics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Antisense and RNAi Therapeutics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 ANTISENSE AND RNAI THERAPEUTICS MARKET PRODUCTION BY REGION
9.1 Global Production of Antisense and RNAi Therapeutics by Region (2019-2024)
9.2 Global Antisense and RNAi Therapeutics Revenue Market Share by Region (2019-2024)
9.3 Global Antisense and RNAi Therapeutics Production, Revenue, Price and Gross Margin (2019-2024)
9.4 North America Antisense and RNAi Therapeutics Production
9.4.1 North America Antisense and RNAi Therapeutics Production Growth Rate (2019-2024)
9.4.2 North America Antisense and RNAi Therapeutics Production, Revenue, Price and Gross Margin (2019-2024)
9.5 Europe Antisense and RNAi Therapeutics Production
9.5.1 Europe Antisense and RNAi Therapeutics Production Growth Rate (2019-2024)
9.5.2 Europe Antisense and RNAi Therapeutics Production, Revenue, Price and Gross Margin (2019-2024)
9.6 Japan Antisense and RNAi Therapeutics Production (2019-2024)
9.6.1 Japan Antisense and RNAi Therapeutics Production Growth Rate (2019-2024)
9.6.2 Japan Antisense and RNAi Therapeutics Production, Revenue, Price and Gross Margin (2019-2024)
9.7 China Antisense and RNAi Therapeutics Production (2019-2024)
9.7.1 China Antisense and RNAi Therapeutics Production Growth Rate (2019-2024)
9.7.2 China Antisense and RNAi Therapeutics Production, Revenue, Price and Gross Margin (2019-2024)
10 KEY COMPANIES PROFILE
10.1 Tekmira Pharmaceuticals
10.1.1 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
10.1.2 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
10.1.3 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product Market Performance
10.1.4 Tekmira Pharmaceuticals Business Overview
10.1.5 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
10.1.6 Tekmira Pharmaceuticals Recent Developments
10.2 Arbutus Biopharma
10.2.1 Arbutus Biopharma Antisense and RNAi Therapeutics Basic Information
10.2.2 Arbutus Biopharma Antisense and RNAi Therapeutics Product Overview
10.2.3 Arbutus Biopharma Antisense and RNAi Therapeutics Product Market Performance
10.2.4 Arbutus Biopharma Business Overview
10.2.5 Arbutus Biopharma Antisense and RNAi Therapeutics SWOT Analysis
10.2.6 Arbutus Biopharma Recent Developments
10.3 Alnylam Pharmaceuticals
10.3.1 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
10.3.2 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
10.3.3 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product Market Performance
10.3.4 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
10.3.5 Alnylam Pharmaceuticals Business Overview
10.3.6 Alnylam Pharmaceuticals Recent Developments
10.4 Antisense Therapeutics
10.4.1 Antisense Therapeutics Antisense and RNAi Therapeutics Basic Information
10.4.2 Antisense Therapeutics Antisense and RNAi Therapeutics Product Overview
10.4.3 Antisense Therapeutics Antisense and RNAi Therapeutics Product Market Performance
10.4.4 Antisense Therapeutics Business Overview
10.4.5 Antisense Therapeutics Recent Developments
10.5 Silence Therapeutics
10.5.1 Silence Therapeutics Antisense and RNAi Therapeutics Basic Information
10.5.2 Silence Therapeutics Antisense and RNAi Therapeutics Product Overview
10.5.3 Silence Therapeutics Antisense and RNAi Therapeutics Product Market Performance
10.5.4 Silence Therapeutics Business Overview
10.5.5 Silence Therapeutics Recent Developments
10.6 Isis Pharmaceuticals
10.6.1 Isis Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
10.6.2 Isis Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
10.6.3 Isis Pharmaceuticals Antisense and RNAi Therapeutics Product Market Performance
10.6.4 Isis Pharmaceuticals Business Overview
10.6.5 Isis Pharmaceuticals Recent Developments
10.7 Sirnaomics
10.7.1 Sirnaomics Antisense and RNAi Therapeutics Basic Information
10.7.2 Sirnaomics Antisense and RNAi Therapeutics Product Overview
10.7.3 Sirnaomics Antisense and RNAi Therapeutics Product Market Performance
10.7.4 Sirnaomics Business Overview
10.7.5 Sirnaomics Recent Developments
10.8 Santaris
10.8.1 Santaris Antisense and RNAi Therapeutics Basic Information
10.8.2 Santaris Antisense and RNAi Therapeutics Product Overview
10.8.3 Santaris Antisense and RNAi Therapeutics Product Market Performance
10.8.4 Santaris Business Overview
10.8.5 Santaris Recent Developments
10.9 Roche
10.9.1 Roche Antisense and RNAi Therapeutics Basic Information
10.9.2 Roche Antisense and RNAi Therapeutics Product Overview
10.9.3 Roche Antisense and RNAi Therapeutics Product Market Performance
10.9.4 Roche Business Overview
10.9.5 Roche Recent Developments
11 ANTISENSE AND RNAI THERAPEUTICS MARKET FORECAST BY REGION
11.1 Global Antisense and RNAi Therapeutics Market Size Forecast
11.2 Global Antisense and RNAi Therapeutics Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Antisense and RNAi Therapeutics Market Size Forecast by Country
11.2.3 Asia Pacific Antisense and RNAi Therapeutics Market Size Forecast by Region
11.2.4 South America Antisense and RNAi Therapeutics Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Antisense and RNAi Therapeutics by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)
12.1 Global Antisense and RNAi Therapeutics Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Antisense and RNAi Therapeutics by Type (2025-2032)
12.1.2 Global Antisense and RNAi Therapeutics Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Antisense and RNAi Therapeutics by Type (2025-2032)
12.2 Global Antisense and RNAi Therapeutics Market Forecast by Application (2025-2032)
12.2.1 Global Antisense and RNAi Therapeutics Sales (K MT) Forecast by Application
12.2.2 Global Antisense and RNAi Therapeutics Market Size (M USD) Forecast by Application (2025-2032)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Antisense and RNAi Therapeutics Market Size Comparison by Region (M USD)
Table 5. Global Antisense and RNAi Therapeutics Sales (K MT) by Manufacturers (2019-2024)
Table 6. Global Antisense and RNAi Therapeutics Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Antisense and RNAi Therapeutics Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Antisense and RNAi Therapeutics Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense and RNAi Therapeutics as of 2022)
Table 10. Global Market Antisense and RNAi Therapeutics Average Price (USD/MT) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Antisense and RNAi Therapeutics Sales Sites and Area Served
Table 12. Manufacturers Antisense and RNAi Therapeutics Product Type
Table 13. Global Antisense and RNAi Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Antisense and RNAi Therapeutics
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Antisense and RNAi Therapeutics Market Challenges
Table 22. Global Antisense and RNAi Therapeutics Sales by Type (K MT)
Table 23. Global Antisense and RNAi Therapeutics Market Size by Type (M USD)
Table 24. Global Antisense and RNAi Therapeutics Sales (K MT) by Type (2019-2024)
Table 25. Global Antisense and RNAi Therapeutics Sales Market Share by Type (2019-2024)
Table 26. Global Antisense and RNAi Therapeutics Market Size (M USD) by Type (2019-2024)
Table 27. Global Antisense and RNAi Therapeutics Market Size Share by Type (2019-2024)
Table 28. Global Antisense and RNAi Therapeutics Price (USD/MT) by Type (2019-2024)
Table 29. Global Antisense and RNAi Therapeutics Sales (K MT) by Application
Table 30. Global Antisense and RNAi Therapeutics Market Size by Application
Table 31. Global Antisense and RNAi Therapeutics Sales by Application (2019-2024) & (K MT)
Table 32. Global Antisense and RNAi Therapeutics Sales Market Share by Application (2019-2024)
Table 33. Global Antisense and RNAi Therapeutics Sales by Application (2019-2024) & (M USD)
Table 34. Global Antisense and RNAi Therapeutics Market Share by Application (2019-2024)
Table 35. Global Antisense and RNAi Therapeutics Sales Growth Rate by Application (2019-2024)
Table 36. Global Antisense and RNAi Therapeutics Sales by Region (2019-2024) & (K MT)
Table 37. Global Antisense and RNAi Therapeutics Sales Market Share by Region (2019-2024)
Table 38. North America Antisense and RNAi Therapeutics Sales by Country (2019-2024) & (K MT)
Table 39. Europe Antisense and RNAi Therapeutics Sales by Country (2019-2024) & (K MT)
Table 40. Asia Pacific Antisense and RNAi Therapeutics Sales by Region (2019-2024) & (K MT)
Table 41. South America Antisense and RNAi Therapeutics Sales by Country (2019-2024) & (K MT)
Table 42. Middle East and Africa Antisense and RNAi Therapeutics Sales by Region (2019-2024) & (K MT)
Table 43. Global Antisense and RNAi Therapeutics Production (K MT) by Region (2019-2024)
Table 44. Global Antisense and RNAi Therapeutics Revenue (US$ Million) by Region (2019-2024)
Table 45. Global Antisense and RNAi Therapeutics Revenue Market Share by Region (2019-2024)
Table 46. Global Antisense and RNAi Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 47. North America Antisense and RNAi Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 48. Europe Antisense and RNAi Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 49. Japan Antisense and RNAi Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 50. China Antisense and RNAi Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 51. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
Table 52. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
Table 53. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 54. Tekmira Pharmaceuticals Business Overview
Table 55. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
Table 56. Tekmira Pharmaceuticals Recent Developments
Table 57. Arbutus Biopharma Antisense and RNAi Therapeutics Basic Information
Table 58. Arbutus Biopharma Antisense and RNAi Therapeutics Product Overview
Table 59. Arbutus Biopharma Antisense and RNAi Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 60. Arbutus Biopharma Business Overview
Table 61. Arbutus Biopharma Antisense and RNAi Therapeutics SWOT Analysis
Table 62. Arbutus Biopharma Recent Developments
Table 63. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
Table 64. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
Table 65. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 66. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
Table 67. Alnylam Pharmaceuticals Business Overview
Table 68. Alnylam Pharmaceuticals Recent Developments
Table 69. Antisense Therapeutics Antisense and RNAi Therapeutics Basic Information
Table 70. Antisense Therapeutics Antisense and RNAi Therapeutics Product Overview
Table 71. Antisense Therapeutics Antisense and RNAi Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 72. Antisense Therapeutics Business Overview
Table 73. Antisense Therapeutics Recent Developments
Table 74. Silence Therapeutics Antisense and RNAi Therapeutics Basic Information
Table 75. Silence Therapeutics Antisense and RNAi Therapeutics Product Overview
Table 76. Silence Therapeutics Antisense and RNAi Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 77. Silence Therapeutics Business Overview
Table 78. Silence Therapeutics Recent Developments
Table 79. Isis Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
Table 80. Isis Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
Table 81. Isis Pharmaceuticals Antisense and RNAi Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 82. Isis Pharmaceuticals Business Overview
Table 83. Isis Pharmaceuticals Recent Developments
Table 84. Sirnaomics Antisense and RNAi Therapeutics Basic Information
Table 85. Sirnaomics Antisense and RNAi Therapeutics Product Overview
Table 86. Sirnaomics Antisense and RNAi Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 87. Sirnaomics Business Overview
Table 88. Sirnaomics Recent Developments
Table 89. Santaris Antisense and RNAi Therapeutics Basic Information
Table 90. Santaris Antisense and RNAi Therapeutics Product Overview
Table 91. Santaris Antisense and RNAi Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 92. Santaris Business Overview
Table 93. Santaris Recent Developments
Table 94. Roche Antisense and RNAi Therapeutics Basic Information
Table 95. Roche Antisense and RNAi Therapeutics Product Overview
Table 96. Roche Antisense and RNAi Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 97. Roche Business Overview
Table 98. Roche Recent Developments
Table 99. Global Antisense and RNAi Therapeutics Sales Forecast by Region (2025-2032) & (K MT)
Table 100. Global Antisense and RNAi Therapeutics Market Size Forecast by Region (2025-2032) & (M USD)
Table 101. North America Antisense and RNAi Therapeutics Sales Forecast by Country (2025-2032) & (K MT)
Table 102. North America Antisense and RNAi Therapeutics Market Size Forecast by Country (2025-2032) & (M USD)
Table 103. Europe Antisense and RNAi Therapeutics Sales Forecast by Country (2025-2032) & (K MT)
Table 104. Europe Antisense and RNAi Therapeutics Market Size Forecast by Country (2025-2032) & (M USD)
Table 105. Asia Pacific Antisense and RNAi Therapeutics Sales Forecast by Region (2025-2032) & (K MT)
Table 106. Asia Pacific Antisense and RNAi Therapeutics Market Size Forecast by Region (2025-2032) & (M USD)
Table 107. South America Antisense and RNAi Therapeutics Sales Forecast by Country (2025-2032) & (K MT)
Table 108. South America Antisense and RNAi Therapeutics Market Size Forecast by Country (2025-2032) & (M USD)
Table 109. Middle East and Africa Antisense and RNAi Therapeutics Consumption Forecast by Country (2025-2032) & (Units)
Table 110. Middle East and Africa Antisense and RNAi Therapeutics Market Size Forecast by Country (2025-2032) & (M USD)
Table 111. Global Antisense and RNAi Therapeutics Sales Forecast by Type (2025-2032) & (K MT)
Table 112. Global Antisense and RNAi Therapeutics Market Size Forecast by Type (2025-2032) & (M USD)
Table 113. Global Antisense and RNAi Therapeutics Price Forecast by Type (2025-2032) & (USD/MT)
Table 114. Global Antisense and RNAi Therapeutics Sales (K MT) Forecast by Application (2025-2032)
Table 115. Global Antisense and RNAi Therapeutics Market Size Forecast by Application (2025-2032) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Antisense and RNAi Therapeutics Market Size Comparison by Region (M USD)
Table 5. Global Antisense and RNAi Therapeutics Sales (K MT) by Manufacturers (2019-2024)
Table 6. Global Antisense and RNAi Therapeutics Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Antisense and RNAi Therapeutics Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Antisense and RNAi Therapeutics Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense and RNAi Therapeutics as of 2022)
Table 10. Global Market Antisense and RNAi Therapeutics Average Price (USD/MT) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Antisense and RNAi Therapeutics Sales Sites and Area Served
Table 12. Manufacturers Antisense and RNAi Therapeutics Product Type
Table 13. Global Antisense and RNAi Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Antisense and RNAi Therapeutics
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Antisense and RNAi Therapeutics Market Challenges
Table 22. Global Antisense and RNAi Therapeutics Sales by Type (K MT)
Table 23. Global Antisense and RNAi Therapeutics Market Size by Type (M USD)
Table 24. Global Antisense and RNAi Therapeutics Sales (K MT) by Type (2019-2024)
Table 25. Global Antisense and RNAi Therapeutics Sales Market Share by Type (2019-2024)
Table 26. Global Antisense and RNAi Therapeutics Market Size (M USD) by Type (2019-2024)
Table 27. Global Antisense and RNAi Therapeutics Market Size Share by Type (2019-2024)
Table 28. Global Antisense and RNAi Therapeutics Price (USD/MT) by Type (2019-2024)
Table 29. Global Antisense and RNAi Therapeutics Sales (K MT) by Application
Table 30. Global Antisense and RNAi Therapeutics Market Size by Application
Table 31. Global Antisense and RNAi Therapeutics Sales by Application (2019-2024) & (K MT)
Table 32. Global Antisense and RNAi Therapeutics Sales Market Share by Application (2019-2024)
Table 33. Global Antisense and RNAi Therapeutics Sales by Application (2019-2024) & (M USD)
Table 34. Global Antisense and RNAi Therapeutics Market Share by Application (2019-2024)
Table 35. Global Antisense and RNAi Therapeutics Sales Growth Rate by Application (2019-2024)
Table 36. Global Antisense and RNAi Therapeutics Sales by Region (2019-2024) & (K MT)
Table 37. Global Antisense and RNAi Therapeutics Sales Market Share by Region (2019-2024)
Table 38. North America Antisense and RNAi Therapeutics Sales by Country (2019-2024) & (K MT)
Table 39. Europe Antisense and RNAi Therapeutics Sales by Country (2019-2024) & (K MT)
Table 40. Asia Pacific Antisense and RNAi Therapeutics Sales by Region (2019-2024) & (K MT)
Table 41. South America Antisense and RNAi Therapeutics Sales by Country (2019-2024) & (K MT)
Table 42. Middle East and Africa Antisense and RNAi Therapeutics Sales by Region (2019-2024) & (K MT)
Table 43. Global Antisense and RNAi Therapeutics Production (K MT) by Region (2019-2024)
Table 44. Global Antisense and RNAi Therapeutics Revenue (US$ Million) by Region (2019-2024)
Table 45. Global Antisense and RNAi Therapeutics Revenue Market Share by Region (2019-2024)
Table 46. Global Antisense and RNAi Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 47. North America Antisense and RNAi Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 48. Europe Antisense and RNAi Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 49. Japan Antisense and RNAi Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 50. China Antisense and RNAi Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 51. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
Table 52. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
Table 53. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 54. Tekmira Pharmaceuticals Business Overview
Table 55. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
Table 56. Tekmira Pharmaceuticals Recent Developments
Table 57. Arbutus Biopharma Antisense and RNAi Therapeutics Basic Information
Table 58. Arbutus Biopharma Antisense and RNAi Therapeutics Product Overview
Table 59. Arbutus Biopharma Antisense and RNAi Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 60. Arbutus Biopharma Business Overview
Table 61. Arbutus Biopharma Antisense and RNAi Therapeutics SWOT Analysis
Table 62. Arbutus Biopharma Recent Developments
Table 63. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
Table 64. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
Table 65. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 66. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
Table 67. Alnylam Pharmaceuticals Business Overview
Table 68. Alnylam Pharmaceuticals Recent Developments
Table 69. Antisense Therapeutics Antisense and RNAi Therapeutics Basic Information
Table 70. Antisense Therapeutics Antisense and RNAi Therapeutics Product Overview
Table 71. Antisense Therapeutics Antisense and RNAi Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 72. Antisense Therapeutics Business Overview
Table 73. Antisense Therapeutics Recent Developments
Table 74. Silence Therapeutics Antisense and RNAi Therapeutics Basic Information
Table 75. Silence Therapeutics Antisense and RNAi Therapeutics Product Overview
Table 76. Silence Therapeutics Antisense and RNAi Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 77. Silence Therapeutics Business Overview
Table 78. Silence Therapeutics Recent Developments
Table 79. Isis Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
Table 80. Isis Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
Table 81. Isis Pharmaceuticals Antisense and RNAi Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 82. Isis Pharmaceuticals Business Overview
Table 83. Isis Pharmaceuticals Recent Developments
Table 84. Sirnaomics Antisense and RNAi Therapeutics Basic Information
Table 85. Sirnaomics Antisense and RNAi Therapeutics Product Overview
Table 86. Sirnaomics Antisense and RNAi Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 87. Sirnaomics Business Overview
Table 88. Sirnaomics Recent Developments
Table 89. Santaris Antisense and RNAi Therapeutics Basic Information
Table 90. Santaris Antisense and RNAi Therapeutics Product Overview
Table 91. Santaris Antisense and RNAi Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 92. Santaris Business Overview
Table 93. Santaris Recent Developments
Table 94. Roche Antisense and RNAi Therapeutics Basic Information
Table 95. Roche Antisense and RNAi Therapeutics Product Overview
Table 96. Roche Antisense and RNAi Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 97. Roche Business Overview
Table 98. Roche Recent Developments
Table 99. Global Antisense and RNAi Therapeutics Sales Forecast by Region (2025-2032) & (K MT)
Table 100. Global Antisense and RNAi Therapeutics Market Size Forecast by Region (2025-2032) & (M USD)
Table 101. North America Antisense and RNAi Therapeutics Sales Forecast by Country (2025-2032) & (K MT)
Table 102. North America Antisense and RNAi Therapeutics Market Size Forecast by Country (2025-2032) & (M USD)
Table 103. Europe Antisense and RNAi Therapeutics Sales Forecast by Country (2025-2032) & (K MT)
Table 104. Europe Antisense and RNAi Therapeutics Market Size Forecast by Country (2025-2032) & (M USD)
Table 105. Asia Pacific Antisense and RNAi Therapeutics Sales Forecast by Region (2025-2032) & (K MT)
Table 106. Asia Pacific Antisense and RNAi Therapeutics Market Size Forecast by Region (2025-2032) & (M USD)
Table 107. South America Antisense and RNAi Therapeutics Sales Forecast by Country (2025-2032) & (K MT)
Table 108. South America Antisense and RNAi Therapeutics Market Size Forecast by Country (2025-2032) & (M USD)
Table 109. Middle East and Africa Antisense and RNAi Therapeutics Consumption Forecast by Country (2025-2032) & (Units)
Table 110. Middle East and Africa Antisense and RNAi Therapeutics Market Size Forecast by Country (2025-2032) & (M USD)
Table 111. Global Antisense and RNAi Therapeutics Sales Forecast by Type (2025-2032) & (K MT)
Table 112. Global Antisense and RNAi Therapeutics Market Size Forecast by Type (2025-2032) & (M USD)
Table 113. Global Antisense and RNAi Therapeutics Price Forecast by Type (2025-2032) & (USD/MT)
Table 114. Global Antisense and RNAi Therapeutics Sales (K MT) Forecast by Application (2025-2032)
Table 115. Global Antisense and RNAi Therapeutics Market Size Forecast by Application (2025-2032) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Antisense and RNAi Therapeutics
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Antisense and RNAi Therapeutics Market Size (M USD), 2019-2032
Figure 5. Global Antisense and RNAi Therapeutics Market Size (M USD) (2019-2032)
Figure 6. Global Antisense and RNAi Therapeutics Sales (K MT) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Antisense and RNAi Therapeutics Market Size by Country (M USD)
Figure 11. Antisense and RNAi Therapeutics Sales Share by Manufacturers in 2023
Figure 12. Global Antisense and RNAi Therapeutics Revenue Share by Manufacturers in 2023
Figure 13. Antisense and RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Antisense and RNAi Therapeutics Average Price (USD/MT) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Antisense and RNAi Therapeutics Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Antisense and RNAi Therapeutics Market Share by Type
Figure 18. Sales Market Share of Antisense and RNAi Therapeutics by Type (2019-2024)
Figure 19. Sales Market Share of Antisense and RNAi Therapeutics by Type in 2023
Figure 20. Market Size Share of Antisense and RNAi Therapeutics by Type (2019-2024)
Figure 21. Market Size Market Share of Antisense and RNAi Therapeutics by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Antisense and RNAi Therapeutics Market Share by Application
Figure 24. Global Antisense and RNAi Therapeutics Sales Market Share by Application (2019-2024)
Figure 25. Global Antisense and RNAi Therapeutics Sales Market Share by Application in 2023
Figure 26. Global Antisense and RNAi Therapeutics Market Share by Application (2019-2024)
Figure 27. Global Antisense and RNAi Therapeutics Market Share by Application in 2023
Figure 28. Global Antisense and RNAi Therapeutics Sales Growth Rate by Application (2019-2024)
Figure 29. Global Antisense and RNAi Therapeutics Sales Market Share by Region (2019-2024)
Figure 30. North America Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 31. North America Antisense and RNAi Therapeutics Sales Market Share by Country in 2023
Figure 32. U.S. Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 33. Canada Antisense and RNAi Therapeutics Sales (K MT) and Growth Rate (2019-2024)
Figure 34. Mexico Antisense and RNAi Therapeutics Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 36. Europe Antisense and RNAi Therapeutics Sales Market Share by Country in 2023
Figure 37. Germany Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 38. France Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 39. U.K. Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 40. Italy Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 41. Russia Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 42. Asia Pacific Antisense and RNAi Therapeutics Sales and Growth Rate (K MT)
Figure 43. Asia Pacific Antisense and RNAi Therapeutics Sales Market Share by Region in 2023
Figure 44. China Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 45. Japan Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 46. South Korea Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 47. India Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 48. Southeast Asia Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 49. South America Antisense and RNAi Therapeutics Sales and Growth Rate (K MT)
Figure 50. South America Antisense and RNAi Therapeutics Sales Market Share by Country in 2023
Figure 51. Brazil Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 52. Argentina Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 53. Columbia Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 54. Middle East and Africa Antisense and RNAi Therapeutics Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa Antisense and RNAi Therapeutics Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 57. UAE Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 58. Egypt Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 59. Nigeria Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 60. South Africa Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 61. Global Antisense and RNAi Therapeutics Production Market Share by Region (2019-2024)
Figure 62. North America Antisense and RNAi Therapeutics Production (K MT) Growth Rate (2019-2024)
Figure 63. Europe Antisense and RNAi Therapeutics Production (K MT) Growth Rate (2019-2024)
Figure 64. Japan Antisense and RNAi Therapeutics Production (K MT) Growth Rate (2019-2024)
Figure 65. China Antisense and RNAi Therapeutics Production (K MT) Growth Rate (2019-2024)
Figure 66. Global Antisense and RNAi Therapeutics Sales Forecast by Volume (2019-2032) & (K MT)
Figure 67. Global Antisense and RNAi Therapeutics Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Antisense and RNAi Therapeutics Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Antisense and RNAi Therapeutics Market Share Forecast by Type (2025-2032)
Figure 70. Global Antisense and RNAi Therapeutics Sales Forecast by Application (2025-2032)
Figure 71. Global Antisense and RNAi Therapeutics Market Share Forecast by Application (2025-2032)
Figure 1. Product Picture of Antisense and RNAi Therapeutics
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Antisense and RNAi Therapeutics Market Size (M USD), 2019-2032
Figure 5. Global Antisense and RNAi Therapeutics Market Size (M USD) (2019-2032)
Figure 6. Global Antisense and RNAi Therapeutics Sales (K MT) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Antisense and RNAi Therapeutics Market Size by Country (M USD)
Figure 11. Antisense and RNAi Therapeutics Sales Share by Manufacturers in 2023
Figure 12. Global Antisense and RNAi Therapeutics Revenue Share by Manufacturers in 2023
Figure 13. Antisense and RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Antisense and RNAi Therapeutics Average Price (USD/MT) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Antisense and RNAi Therapeutics Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Antisense and RNAi Therapeutics Market Share by Type
Figure 18. Sales Market Share of Antisense and RNAi Therapeutics by Type (2019-2024)
Figure 19. Sales Market Share of Antisense and RNAi Therapeutics by Type in 2023
Figure 20. Market Size Share of Antisense and RNAi Therapeutics by Type (2019-2024)
Figure 21. Market Size Market Share of Antisense and RNAi Therapeutics by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Antisense and RNAi Therapeutics Market Share by Application
Figure 24. Global Antisense and RNAi Therapeutics Sales Market Share by Application (2019-2024)
Figure 25. Global Antisense and RNAi Therapeutics Sales Market Share by Application in 2023
Figure 26. Global Antisense and RNAi Therapeutics Market Share by Application (2019-2024)
Figure 27. Global Antisense and RNAi Therapeutics Market Share by Application in 2023
Figure 28. Global Antisense and RNAi Therapeutics Sales Growth Rate by Application (2019-2024)
Figure 29. Global Antisense and RNAi Therapeutics Sales Market Share by Region (2019-2024)
Figure 30. North America Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 31. North America Antisense and RNAi Therapeutics Sales Market Share by Country in 2023
Figure 32. U.S. Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 33. Canada Antisense and RNAi Therapeutics Sales (K MT) and Growth Rate (2019-2024)
Figure 34. Mexico Antisense and RNAi Therapeutics Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 36. Europe Antisense and RNAi Therapeutics Sales Market Share by Country in 2023
Figure 37. Germany Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 38. France Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 39. U.K. Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 40. Italy Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 41. Russia Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 42. Asia Pacific Antisense and RNAi Therapeutics Sales and Growth Rate (K MT)
Figure 43. Asia Pacific Antisense and RNAi Therapeutics Sales Market Share by Region in 2023
Figure 44. China Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 45. Japan Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 46. South Korea Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 47. India Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 48. Southeast Asia Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 49. South America Antisense and RNAi Therapeutics Sales and Growth Rate (K MT)
Figure 50. South America Antisense and RNAi Therapeutics Sales Market Share by Country in 2023
Figure 51. Brazil Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 52. Argentina Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 53. Columbia Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 54. Middle East and Africa Antisense and RNAi Therapeutics Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa Antisense and RNAi Therapeutics Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 57. UAE Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 58. Egypt Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 59. Nigeria Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 60. South Africa Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (K MT)
Figure 61. Global Antisense and RNAi Therapeutics Production Market Share by Region (2019-2024)
Figure 62. North America Antisense and RNAi Therapeutics Production (K MT) Growth Rate (2019-2024)
Figure 63. Europe Antisense and RNAi Therapeutics Production (K MT) Growth Rate (2019-2024)
Figure 64. Japan Antisense and RNAi Therapeutics Production (K MT) Growth Rate (2019-2024)
Figure 65. China Antisense and RNAi Therapeutics Production (K MT) Growth Rate (2019-2024)
Figure 66. Global Antisense and RNAi Therapeutics Sales Forecast by Volume (2019-2032) & (K MT)
Figure 67. Global Antisense and RNAi Therapeutics Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Antisense and RNAi Therapeutics Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Antisense and RNAi Therapeutics Market Share Forecast by Type (2025-2032)
Figure 70. Global Antisense and RNAi Therapeutics Sales Forecast by Application (2025-2032)
Figure 71. Global Antisense and RNAi Therapeutics Market Share Forecast by Application (2025-2032)
